trending Market Intelligence /marketintelligence/en/news-insights/trending/lcezt0j_8al77m4hkuacwa2 content esgSubNav
In This List

OncoMed names CEO

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


OncoMed names CEO

Redwood City, Calif.-based OncoMed Pharmaceuticals Inc. appointed John Lewicki as its CEO.

Lewicki, who will also join the company's board, will remain the company's president — a position he assumed in January.

Lewicki originally joined OncoMed in 2004 as senior vice president of research and development. He will lead the company as it advances its cancer treatments through clinical development.

He replaces Paul Hastings as CEO, who resigned at the beginning of 2018.